Insider Trading: Samuel Isaly’s Orbimed Advisors is Selling $ANTH

Samuel Isaly’s Orbimed Advisors filed for its recent insider sales in Anthera Pharmaceuticals Inc (ANTH) on November 18th. According to the filing, Orbimed Advisors sold 52 thousand shares in ANTH from November 16 to 18. The average selling price per share was about $6.76. After that Orbimed Advisors still remains 2.89 million shares in its ANTH position, corresponding to a 6.88% activist stake ownership. This is the second insider filing in ANTH revealed by Orbimed Advisors after the third quarter. Before November 16th, Orbimed Advisors sold 60 thousand shares at about $6.94 per share. Orbimed Advisors did not change its position during the third quarter when the firm took 3 million shares in the stock. ANTH has gained 24% so far in 2011. The stock is now trading at $6.05.

Fourteen hedge funds were bullish about ANTH based on their positions in the second quarter. Beside Orbimed Advisors’ largest stake among the hedge funds, Jacob Gottlieb’s Visium Asset Management increased its position by 19% to 1.91 million shares. Roberto Mignone’s Bridger Management took the third with its 1.33 million shares position.


Orbimed is the world’s largest healthcare-dedicated investment firm. The firm has with approximately $5 billion in assets under management. The firm was founded in 1989 with a vision to invest across the spectrum of healthcare companies. The firm manages a series of venture capital funds and public equity investment funds.

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company. The company focuses on developing and commercializing products to treat serious diseases including cardiovascular and autoimmune diseases. The company had one Phase 3 clinical program and two Phase 2 clinical programs as of December 2010. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!